Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
about
The toxicology of bath salts: a review of synthetic cathinonesImpact of the emergence of designer drugs upon sports doping testingKetamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSnIdentification of small molecules using accurate mass MS/MS searchTesting an alternative search algorithm for compound identification with the 'Wiley Registry of Tandem Mass Spectral Data, MSforID'.Applying Tandem Mass Spectral Libraries for Solving the Critical Assessment of Small Molecule Identification (CASMI) LC/MS Challenge 2012.Drop-on-demand sample introduction system coupled with the flowing atmospheric-pressure afterglow for direct molecular analysis of complex liquid microvolume samples.Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urineTowards a universal LC-MS screening procedure - can an LIT LC-MS(n) screening approach and reference library be used on a quadrupole-LIT hybrid instrument?New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine.On the inter-instrument and the inter-laboratory transferability of a tandem mass spectral reference library. 3. Focus on ion trap and upfront CID.2-methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques.A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine.The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC-MS, LC-MSn, and LC-HR-MSn.Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS.Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MS(n), and LC-high resolution-MS/MS.Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP).Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MSn , and LC-HR-MSn.A simple extraction and LC-MS/MS approach for the screening and identification of over 100 analytes in eight different matrices.Compound identification in forensic toxicological analysis with untargeted LC-MS-based techniques.Broad Screening and Identification of Novel Psychoactive Substances in Plasma by High-Performance Liquid Chromatography-High-Resolution Mass Spectrometry and Post-run Library Matching.Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry.Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents.Aspects of matrix effects in applications of liquid chromatography-mass spectrometry to forensic and clinical toxicology--a review.Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS.Methods for urine drug testing using one-step dilution and direct injection in combination with LC-MS/MS and LC-HRMS.Power of Orbitrap-based LC-high resolution-MS/MS for comprehensive drug testing in urine with or without conjugate cleavage or using dried urine spots after on-spot cleavage in comparison to established LC-MSn or GC-MS procedures.Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology.New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver Preparations and their Detectability in Urine by GC-MS, "LC-(High Resolution)-MSn" and "Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques.Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-HR-MS/MS.Fast screening of 88 pharmaceutical drugs and metabolites in whole blood by ultrahigh-performance liquid chromatography-tandem mass spectrometry.GC-MS, LC-MS(n), LC-high resolution-MS(n), and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high "Kanna" isolated from Sceletium tortuosum.Diagnosis of Heroin Overdose in an 8-Year-Old Boy: Reliable Contribution of Toxicological Investigations.Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography-linear ion-trap (high-resolution) mass spectrometry.Screening of stimulants including designer drugs in urine using a liquid chromatography tandem mass spectrometry system.Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography-linear ion trap-mass spectrometry (LC-MS(n)).Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn , and LC-HR-MS/MS.Assessment of maternal drug intake by urinary bio monitoring during pregnancy and postpartally until the third perinatal year.
P2860
Q28253719-2D56AC96-0707-4749-8348-2E5C9648EB42Q28255977-F31256E7-7337-463B-918B-ECCA4998D75FQ28292983-DCCDD68C-5B04-48E4-8DF5-8E26B3644815Q29994570-D807056A-3A43-4B44-9155-050E2740EE62Q30616528-99D61BBC-C28F-4BF4-809F-B5BD9BD04AE0Q31167360-F85AA52E-FADE-4059-886A-BC5250D04D42Q33456011-AF236E87-F426-42F8-AD5D-6513B5BC4590Q34022671-189ECEF6-9CB2-42E1-AAEA-A7577B66F4E0Q34142688-D2BDDFD1-C20A-44E2-ADD4-5E2BC29B94C7Q34167745-AAAB0ADC-07FB-45F2-942A-8264A623E5F0Q34167752-D6B6156E-E04B-42C3-8F78-CE2ECBDEB30DQ34325128-AF4737D8-2A52-48E3-A3D3-C9D9160C8B1BQ34364856-5817D70F-E91D-4A83-9493-93B12159D4D3Q34377572-E53498B1-5D7E-4494-BFD7-F5314EEA8A0EQ34378886-412F9417-77A2-44AC-B18A-6F727B9654C4Q34408021-E0310A34-0699-4489-90CF-8E4427665130Q34457560-C2FE21FD-E3C4-4E0E-9E10-61B1F24465ACQ34497670-1F674AF8-084A-4B8B-A66F-CA8DBC3AB576Q34510789-D7027FFB-06B0-473E-ACF1-A3CBFC3FAE40Q35154396-CFA83EC5-4EBE-4A88-94B8-90AF89512BA8Q35840290-5C86E57A-8758-4D3B-89F0-DE1C5EF2BC16Q36088120-71FA92D7-9F6B-47D6-8F1E-B510BC3138E6Q37658304-37CFB9FC-0533-4560-BA32-E4B43966EAF6Q37922114-B627D9F3-805C-4A21-B087-DA0769D14BB5Q38006891-D7F7D8B2-9B12-4E52-9263-B0200E5F309BQ38260819-A3FD8F1E-0129-4A65-A83E-3A25A1934CC8Q38266513-5F8B60F1-D5D5-4F4C-9C19-55F8121E0B6CQ38654007-DB81334F-E218-4075-94FB-1D4F0435DFCBQ38754171-F7574BEF-5668-4C4A-AC91-B2AB4BC49AB8Q39272650-CC7A2EB8-94BA-4509-9BBF-E624503991A3Q40903642-DC54B768-9510-47F8-A0EA-5C622052258AQ44806049-3D5334AB-4704-4070-A9DE-B4DA7410C4F7Q45396704-AEBD606F-16AA-40C2-8DC2-1FF6315B9B27Q46836046-ACA01F25-71FA-4757-8102-B3DACC0DC2B2Q47664046-9C60434D-839D-4E9A-B711-E2AC1C0BA648Q47921568-DEA0D8A1-8FB2-4C56-9F33-91FD79A9C08BQ48099182-0D26A53D-2BC5-478A-8AA0-8C609C817DF7Q48216283-617DD1CB-44FF-484D-A153-0093DD20C681Q48362650-7497F1CD-7B09-423D-8C5F-E3A297CCA34AQ50949045-7A3B9A49-429E-41C6-A0E0-FBB9F67A0F8B
P2860
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
@ast
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
@en
type
label
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
@ast
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
@en
prefLabel
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
@ast
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
@en
P2093
P2860
P1476
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
@en
P2093
Anika A Philipp
Armin A Weber
Daniela Remane
Dirk K Wissenbach
Hans H Maurer
Markus R Meyer
P2860
P2888
P304
P356
10.1007/S00216-011-5032-1
P407
P577
2011-05-01T00:00:00Z